Engineering, decoding and systems-level characterization of chimpanzee cytomegalovirus.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
01 2022
Historique:
received: 28 07 2021
accepted: 09 12 2021
revised: 14 01 2022
pubmed: 5 1 2022
medline: 19 2 2022
entrez: 4 1 2022
Statut: epublish

Résumé

The chimpanzee cytomegalovirus (CCMV) is the closest relative of human CMV (HCMV). Because of the high conservation between these two species and the ability of human cells to fully support CCMV replication, CCMV holds great potential as a model system for HCMV. To make the CCMV genome available for precise and rapid gene manipulation techniques, we captured the genomic DNA of CCMV strain Heberling as a bacterial artificial chromosome (BAC). Selected BAC clones were reconstituted to infectious viruses, growing to similar high titers as parental CCMV. DNA sequencing confirmed the integrity of our clones and led to the identification of two polymorphic loci and a deletion-prone region within the CCMV genome. To re-evaluate the CCMV coding potential, we analyzed the viral transcriptome and proteome and identified several novel ORFs, splice variants, and regulatory RNAs. We further characterized the dynamics of CCMV gene expression and found that viral proteins cluster into five distinct temporal classes. In addition, our datasets revealed that the host response to CCMV infection and the de-regulation of cellular pathways are in line with known hallmarks of HCMV infection. In a first functional experiment, we investigated a proposed frameshift mutation in UL128 that was suspected to restrict CCMV's cell tropism. In fact, repair of this frameshift re-established productive CCMV infection in endothelial and epithelial cells, expanding the options of CCMV as an infection model. Thus, BAC-cloned CCMV can serve as a powerful tool for systematic approaches in comparative functional genomics, exploiting the close phylogenetic relationship between CCMV and HCMV.

Identifiants

pubmed: 34982803
doi: 10.1371/journal.ppat.1010193
pii: PPATHOGENS-D-21-01572
pmc: PMC8759705
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010193

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6104-6109
pubmed: 28533400
J Virol. 2020 Feb 14;94(5):
pubmed: 31801856
J Virol. 2012 Sep;86(17):8959-73
pubmed: 22718821
Genes Dev. 2019 Aug 1;33(15-16):1008-1026
pubmed: 31123061
Nat Microbiol. 2019 Dec;4(12):2260-2272
pubmed: 31548682
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
mSphere. 2017 Oct 4;2(5):
pubmed: 28989973
J Gen Virol. 1992 Dec;73 ( Pt 12):3281-4
pubmed: 1335029
Cell Host Microbe. 2014 Aug 13;16(2):201-214
pubmed: 25121749
RNA Biol. 2019 Feb;16(2):166-175
pubmed: 30608222
Viruses. 2017 Sep 02;9(9):
pubmed: 28869497
J Gen Virol. 2009 Oct;90(Pt 10):2386-2394
pubmed: 19553394
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8
pubmed: 14623981
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
Front Microbiol. 2019 May 15;10:1005
pubmed: 31156572
Sci Rep. 2018 Mar 13;8(1):4447
pubmed: 29535361
Biochem Biophys Res Commun. 2001 Feb 2;280(4):1093-100
pubmed: 11162639
Med Microbiol Immunol. 2008 Jun;197(2):109-15
pubmed: 18193454
J Virol. 2013 Aug;87(15):8651-64
pubmed: 23720731
Cell Host Microbe. 2021 Jan 13;29(1):121-131.e4
pubmed: 33290720
Cell. 2014 Jun 5;157(6):1460-1472
pubmed: 24906157
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401
pubmed: 14519856
Oncogene. 2004 Mar 15;23(11):1972-84
pubmed: 15021885
J Gen Virol. 2003 May;84(Pt 5):1117-1122
pubmed: 12692276
PLoS Pathog. 2012 Sep;8(9):e1002908
pubmed: 22969428
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19755-60
pubmed: 22109557
Rev Med Virol. 2004 Nov-Dec;14(6):383-410
pubmed: 15386592
Anal Biochem. 1984 Apr;138(1):141-3
pubmed: 6731838
J Virol. 1999 Oct;73(10):8320-9
pubmed: 10482582
Philos Ethics Humanit Med. 2008 Jun 02;3:16
pubmed: 18518999
Cell Rep. 2020 Oct 6;33(1):108235
pubmed: 33027661
Trends Genet. 2000 Jun;16(6):254-9
pubmed: 10827452
Cell Syst. 2016 Oct 26;3(4):361-373.e6
pubmed: 27641956
J Virol. 1991 Oct;65(10):5184-9
pubmed: 1654438
mSystems. 2019 Oct 1;4(5):
pubmed: 31575665
J Virol. 2018 Aug 29;92(18):
pubmed: 29997207
J Gen Virol. 2008 Feb;89(Pt 2):359-368
pubmed: 18198366
J Mol Biol. 1967 Jun 14;26(2):365-9
pubmed: 4291934
J Struct Biol. 2011 Jun;174(3):451-60
pubmed: 21459145
J Virol. 2007 Aug;81(15):7860-72
pubmed: 17522202
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
PLoS Pathog. 2015 Nov 24;11(11):e1005288
pubmed: 26599541
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Gen Virol. 2006 Oct;87(Pt 10):2849-2858
pubmed: 16963742
Cell Mol Immunol. 2015 Mar;12(2):139-53
pubmed: 25418469
PLoS Pathog. 2016 Nov 9;12(11):e1006014
pubmed: 27829026
J Virol. 2002 Mar;76(5):2316-28
pubmed: 11836410
PLoS Pathog. 2010 Sep 09;6(9):e1001096
pubmed: 20844576
PLoS Pathog. 2021 Jan 26;17(1):e1009088
pubmed: 33497413
Front Immunol. 2019 Jun 10;10:1155
pubmed: 31244824
PLoS Pathog. 2011 May;7(5):e1001344
pubmed: 21625576
mBio. 2021 May 4;12(3):
pubmed: 33947766
Rev Med Virol. 2001 May-Jun;11(3):191-200
pubmed: 11376481
Biotechniques. 2017 Nov 1;63(5):205-214
pubmed: 29185920
PLoS Pathog. 2020 Apr 15;16(4):e1008390
pubmed: 32294138
Proc Natl Acad Sci U S A. 2018 May 8;115(19):4998-5003
pubmed: 29691324
Virus Evol. 2019 Aug 01;5(2):vez015
pubmed: 31384482
Elife. 2019 Dec 24;8:
pubmed: 31873071
Nat Rev Immunol. 2020 Feb;20(2):113-127
pubmed: 31666730
J Virol. 2016 Jan 13;90(6):3229-42
pubmed: 26764006
J Gen Virol. 2003 Jan;84(Pt 1):17-28
pubmed: 12533697
PLoS Pathog. 2020 May 8;16(5):e1008476
pubmed: 32384127
Med Microbiol Immunol. 2015 Jun;204(3):273-84
pubmed: 25894764
Curr Opin Virol. 2017 Aug;25:126-133
pubmed: 28888133
Cell Rep. 2019 Jul 9;28(2):434-448.e6
pubmed: 31291579
Viruses. 2019 Mar 19;11(3):
pubmed: 30893762
Front Microbiol. 2020 Apr 15;11:661
pubmed: 32351486
Med Microbiol Immunol. 2015 Jun;204(3):409-19
pubmed: 25776080
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
J Virol. 2001 Apr;75(8):3613-25
pubmed: 11264351
Nature. 2020 Jun;582(7813):561-565
pubmed: 32365353
J Virol. 2016 Mar 28;90(8):3929-43
pubmed: 26842472
Virology. 2009 Dec 5;395(1):21-32
pubmed: 19818982
J Biomed Biotechnol. 2012;2012:472537
pubmed: 22496607
Front Microbiol. 2016 Jun 06;7:869
pubmed: 27375590
BMC Biol. 2006 Dec 07;4:41
pubmed: 17156431
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
J Gen Virol. 2016 Jan;97(1):196-208
pubmed: 26555021
J Infect Dis. 2020 Mar 5;221(Suppl 1):S60-S73
pubmed: 32134481
J Virol. 2020 Jan 6;94(2):
pubmed: 31694945
PLoS Pathog. 2020 Nov 24;16(11):e1008666
pubmed: 33232376
Cell Host Microbe. 2018 Sep 12;24(3):447-460.e11
pubmed: 30122656
Curr Top Microbiol Immunol. 2008;325:63-83
pubmed: 18637500
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):E8885-E8894
pubmed: 28928148
J Virol. 2006 Jun;80(11):5588-98
pubmed: 16699040

Auteurs

Quang Vinh Phan (QV)

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Boris Bogdanow (B)

Department of Structural Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Emanuel Wyler (E)

Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

Markus Landthaler (M)

Berlin Institute for Medical Systems Biology, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.

Fan Liu (F)

Department of Structural Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany.

Christian Hagemeier (C)

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Lüder Wiebusch (L)

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH